<strong>Objective: </strong><span style="font-family:""><span style="font-family:Verdana;">To investigate the clinical effects of</span><a name="_Hlk26140...<strong>Objective: </strong><span style="font-family:""><span style="font-family:Verdana;">To investigate the clinical effects of</span><a name="_Hlk26140736"></a><span style="font-family:Verdana;"> recombinant human interleukin-2 (rhIL-2) combined with </span><a name="_Hlk26140744"></a><span style="font-family:Verdana;">Zhenqi Fuzheng and Baofukang on cervical intraepithelial neoplasia II (CINII) combined with human papilloma virus infection. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">There were 593 patients diagnosed with CINII with HPV infection, including 296 in the control group and 297 in the experimental group. The control group was given only Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine. The experimental group was treated with rhIL-2 injection in addition to Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine which is treated for 3 months. After 3 months, Thinprep cytologic test (TCT), human papilloma virus (HPV) quantitative examination and colposcopy biopsy were reviewed. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> After 3 months of treatment, the negative conversion rate and total effective rate of HPV in the control group were 58.11% and 70.95% respectively, and the negative conversion rate and total effective rate of the experimental group were 79.46% and 90.57% respectively. There was significant difference between the two groups (p = 0.000). The curative rate of cervical lesions was significantly higher in the test group than in the control group, 89.56%, 68.91%, respectively. The statistical difference between the two groups is significant (p = 0.000). </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> It has an essential clinical value that HPV infection patients and cervical intraepithelial neoplasia II associated with </span><a name="_Hlk47768779"></a><span style="font-family:Verdana;">HPV infection patients are treated by rhIL-2 combined with Zhenqifuzheng and Baofukang, </span><a name="_Hlk47805707"></a><span style="font-family:Verdana;">which is safe, effective, non-invasive, reusable advantages. However, the long-term efficacy and side effects need to be further studied.</span></span>展开更多
目的探讨黄芪多糖诱导成熟的树突状细胞(DC)肿瘤疫苗对S180荷瘤小鼠的抗肿瘤作用及作用机制。方法体外培养小鼠骨髓来源的DC,加入黄芪多糖诱导成熟,以S180肿瘤抗原致敏获得DC肿瘤疫苗。建立S180荷瘤小鼠模型,分为模型组、环磷酰胺组、...目的探讨黄芪多糖诱导成熟的树突状细胞(DC)肿瘤疫苗对S180荷瘤小鼠的抗肿瘤作用及作用机制。方法体外培养小鼠骨髓来源的DC,加入黄芪多糖诱导成熟,以S180肿瘤抗原致敏获得DC肿瘤疫苗。建立S180荷瘤小鼠模型,分为模型组、环磷酰胺组、黄芪多糖组、细胞因子组,在荷瘤第5天和第10天分别给予相应治疗。荷瘤第12天摘取肿瘤组织、胸腺、脾脏称质量,计算抑瘤率、胸腺指数、脾脏指数;ELISA法检测小鼠血清白细胞介素(IL)-4、干扰素(IFN)-γ水平。结果黄芪多糖组、细胞因子组的抑瘤率高于环磷酰胺组(64.25%、64.10%vs35.11%),胸腺指数高于环磷酰胺组(1.69±0.26、1.74±0.38 vs 1.45±0.22),脾脏指数高于环磷酰胺组(5.44±0.76、5.31±0.81 vs 3.54±0.52),IL-4水平(ng/L)低于环磷酰胺组(15.66±2.57、14.72±4.84 vs 23.95±6.07),IFN-γ水平(ng/L)高于环磷酰胺组(16.54±3.71、17.20±2.03 vs 10.37±2.19),差异均有统计学意义。结论黄芪多糖诱导的DC疫苗可有效发挥抑瘤作用,其机制可能与提高荷瘤小鼠胸腺指数与脾脏指数,调节细胞因子表达,促进Th1/Th2失衡向Th1细胞占优势的细胞免疫偏移,增强机体的抗肿瘤免疫功能有关。展开更多
文摘<strong>Objective: </strong><span style="font-family:""><span style="font-family:Verdana;">To investigate the clinical effects of</span><a name="_Hlk26140736"></a><span style="font-family:Verdana;"> recombinant human interleukin-2 (rhIL-2) combined with </span><a name="_Hlk26140744"></a><span style="font-family:Verdana;">Zhenqi Fuzheng and Baofukang on cervical intraepithelial neoplasia II (CINII) combined with human papilloma virus infection. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">There were 593 patients diagnosed with CINII with HPV infection, including 296 in the control group and 297 in the experimental group. The control group was given only Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine. The experimental group was treated with rhIL-2 injection in addition to Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine which is treated for 3 months. After 3 months, Thinprep cytologic test (TCT), human papilloma virus (HPV) quantitative examination and colposcopy biopsy were reviewed. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> After 3 months of treatment, the negative conversion rate and total effective rate of HPV in the control group were 58.11% and 70.95% respectively, and the negative conversion rate and total effective rate of the experimental group were 79.46% and 90.57% respectively. There was significant difference between the two groups (p = 0.000). The curative rate of cervical lesions was significantly higher in the test group than in the control group, 89.56%, 68.91%, respectively. The statistical difference between the two groups is significant (p = 0.000). </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> It has an essential clinical value that HPV infection patients and cervical intraepithelial neoplasia II associated with </span><a name="_Hlk47768779"></a><span style="font-family:Verdana;">HPV infection patients are treated by rhIL-2 combined with Zhenqifuzheng and Baofukang, </span><a name="_Hlk47805707"></a><span style="font-family:Verdana;">which is safe, effective, non-invasive, reusable advantages. However, the long-term efficacy and side effects need to be further studied.</span></span>
文摘目的探讨黄芪多糖诱导成熟的树突状细胞(DC)肿瘤疫苗对S180荷瘤小鼠的抗肿瘤作用及作用机制。方法体外培养小鼠骨髓来源的DC,加入黄芪多糖诱导成熟,以S180肿瘤抗原致敏获得DC肿瘤疫苗。建立S180荷瘤小鼠模型,分为模型组、环磷酰胺组、黄芪多糖组、细胞因子组,在荷瘤第5天和第10天分别给予相应治疗。荷瘤第12天摘取肿瘤组织、胸腺、脾脏称质量,计算抑瘤率、胸腺指数、脾脏指数;ELISA法检测小鼠血清白细胞介素(IL)-4、干扰素(IFN)-γ水平。结果黄芪多糖组、细胞因子组的抑瘤率高于环磷酰胺组(64.25%、64.10%vs35.11%),胸腺指数高于环磷酰胺组(1.69±0.26、1.74±0.38 vs 1.45±0.22),脾脏指数高于环磷酰胺组(5.44±0.76、5.31±0.81 vs 3.54±0.52),IL-4水平(ng/L)低于环磷酰胺组(15.66±2.57、14.72±4.84 vs 23.95±6.07),IFN-γ水平(ng/L)高于环磷酰胺组(16.54±3.71、17.20±2.03 vs 10.37±2.19),差异均有统计学意义。结论黄芪多糖诱导的DC疫苗可有效发挥抑瘤作用,其机制可能与提高荷瘤小鼠胸腺指数与脾脏指数,调节细胞因子表达,促进Th1/Th2失衡向Th1细胞占优势的细胞免疫偏移,增强机体的抗肿瘤免疫功能有关。
